Previous 10 | Next 10 |
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD Anderson Cancer Center exercised its option to license Bellicumȁ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Bellicum Pharmaceuticals, Inc. (NasdaqGM: BLCM). Beginning in May 2017, the Company made ...
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling synergizes with transgenic IL-15 production to improve CAR-NK cell proliferation and pe...
Bellicum Pharmaceuticals ( BLCM -25% ) slumps on 20% higher volume in apparent reaction to an ASH abstract related to T cell therapy rivogenlecleucel (rivo-cel) (formerly BPX-501). More news on: Bellicum Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read...
Gainers : Camber Energy (NYSEMKT: CEI ) +50% . Asta Funding (NASDAQ: ASFI ) +44% . Wright Medical Group N.V. (NASDAQ: WMGI ) +32% . Agile Therapeutics (NASDAQ: AGRX ) +31% . YRC Worldwide (NASDAQ: YRCW ) +26% . Bellicum Pharmaceuticals (NASDAQ: BLCM ) +23% . Superior...
Nano cap Bellicum Pharmaceuticals ( BLCM +26.2% ) jumps on a 2.5x surge in volume, adding to its 30% move on Friday. More news on: Bellicum Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Camber Energy (NYSEMKT: CEI ) +53% . More news on: Camber Energy, Inc., Wright Medical Group N.V., Enlivex Therapeutics Ltd., Stocks on the move, Read more ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the green last week, soaring from 3,322.49 points on Monday’s (October 28) open to reach 3,442.25 points as of 1:28 p.m. EDT on Friday (November 1), representing a 3.35 percent increase during the week. On Wednesday (October 30...
HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract for a preclinical investigation from its natural killer cell chimeric antigen receptor (...
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT - HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for can...
News, Short Squeeze, Breakout and More Instantly...
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...